{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:16:48Z","timestamp":1784557008324,"version":"3.55.0"},"reference-count":10,"publisher":"Bioscientifica","content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,6,8]]},"abstract":"Summary<\/jats:title>\n Pituitary apoplexy represents an uncommon endocrine emergency with potentially life-threatening consequences. Drug-induced pituitary apoplexy is a rare but important consideration when evaluating patients with this presentation. We describe an unusual case of a patient with a known pituitary macroadenoma presenting with acute-onset third nerve palsy and headache secondary to tumour enlargement and apoplexy. This followed gonadotropin-releasing hormone (GNRH) agonist therapy used to treat metastatic prostate carcinoma. Following acute management, the patient underwent transphenoidal debulking of his pituitary gland with resolution of his third nerve palsy. Subsequent retrospective data interpretation revealed that this had been a secretory gonadotropinoma and GNRH agonist therapy resulted in raised gonadotropins and testosterone. Hence, further management of his prostate carcinoma required GNRH antagonist therapy and external beam radiotherapy. This case demonstrates an uncommon complication of GNRH agonist therapy in the setting of a pituitary macroadenoma. It also highlights the importance of careful, serial data interpretation in patients with pituitary adenomas. Finally, this case presents a unique insight into the challenges of managing a hormonal-dependent prostate cancer in a patient with a secretory pituitary tumour.<\/jats:p>\n \n Learning points<\/jats:title>\n \n \n \n While non-functioning gonadotropinomas represent the most common form of pituitary macroadenoma, functioning gonadotropinomas are exceedingly rare.<\/jats:p>\n <\/jats:list-item>\n \n Acute tumour enlargement, with potential pituitary apoplexy, is a rare but important adverse effect arising from GNRH agonist therapy in the presence of both functioning and non-functioning pituitary gonadotropinomas.<\/jats:p>\n <\/jats:list-item>\n \n GNRH antagonist therapy represents an alternative treatment option for patients with hormonal therapy-requiring prostate cancer, who also have diagnosed with a pituitary gonadotropinoma.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1530\/edm-16-0021","type":"journal-article","created":{"date-parts":[[2016,6,7]],"date-time":"2016-06-07T06:37:57Z","timestamp":1465281477000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":6,"title":["Gonadotropin-releasing hormone agonist-induced pituitary apoplexy"],"prefix":"10.1530","volume":"2016","author":[{"given":"Fergus","family":"Keane","sequence":"first","affiliation":[{"name":"1Department of Endocrinology, University Hospital Galway, Newcastle, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife M","family":"Egan","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, University Hospital Galway, Newcastle, Galway, Ireland"},{"name":"3School of Medicine, National University of Ireland Galway, Newcastle, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Navin","sequence":"additional","affiliation":[{"name":"2Department of Radiology, University Hospital Galway, Newcastle, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Brett","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Beaumont Hospital, Beaumont Road, Dublin 9, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C","family":"Dennedy","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, University Hospital Galway, Newcastle, Galway, Ireland"},{"name":"3School of Medicine, National University of Ireland Galway, Newcastle, Galway, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"key20161005112645983_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2265.1999.00754.x","article-title":"Classical pituitary apoplexy: clinical features, management and outcome","volume":"51","author":"Randeva","year":"1999","journal-title":"Clinical Endocrinology"},{"key":"key20161005112645983_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11102-009-0202-2","article-title":"Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer","volume":"13","author":"Guerra","year":"2010","journal-title":"Pituitary"},{"key":"key20161005112645983_bib3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1750-3639.2012.00599.x","article-title":"Clinicopathological correlations in pituitary adenomas","volume":"22","author":"Mete","year":"2012","journal-title":"Brain Pathology"},{"key":"key20161005112645983_bib4","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1210\/jc.2014-2362","article-title":"Functioning gonadotroph adenomas","volume":"99","author":"Ntali","year":"2014","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"key20161005112645983_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jocn.2014.08.015","article-title":"Pituitary apoplexy following gonadotropin-releasing hormone agonist administration with secreting pituitary adenoma","volume":"3","author":"Sasagawa","year":"2015","journal-title":"Journal of Clinical Neuroscience"},{"key":"key20161005112645983_bib6","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1517\/14656566.5.6.1287","article-title":"Management of pituitary apoplexy","volume":"5","author":"Chanson","year":"2004","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"key20161005112645983_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2265.1996.644465.x","article-title":"Pituitary apoplexy after leuprolide administration for carcinoma of the prostate","volume":"44","author":"Morsi","year":"1996","journal-title":"Clinical Endocrinology"},{"key":"key20161005112645983_bib8","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(95)90443-3","article-title":"Pituitary apoplexy after goserelin","volume":"345","author":"Ando","year":"1995","journal-title":"Lancet"},{"key":"key20161005112645983_bib9","first-page":"2267","article-title":"Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma","volume":"80","author":"Hanson","year":"1995","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"key20161005112645983_bib10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00228-014-1682-1","article-title":"Clinical pharmacology and regulatory consequenes of GnRH analogues in prostate cancer","volume":"70","author":"Eckstein","year":"2014","journal-title":"European Journal of Clinical Pharmacology"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2016\/1\/EDM16-0021.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/downloadpdf\/journals\/edm\/2016\/1\/EDM16-0021.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:46:17Z","timestamp":1784555177000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,8]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1530\/edm-16-0021","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,8]]}}}